SAN
JOSE, Calif., Oct. 31,
2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:
ANIX), a biotechnology company focused on the treatment and
prevention of cancer and infectious diseases, today announced that
the inventor of its ovarian cancer CAR-T technology, Dr.
Jose Conejo-Garcia, Senior Member of
the Immunology Department at Moffitt Cancer Center, has been
invited to be the keynote speaker at Duke Cancer Institute's
Immuno-Oncology Research Program Retreat on November 4, 2022.
During the presentation, Dr. Conejo-Garcia will discuss the
CAR-T technology, which is an autologous cell therapy comprised of
engineered T-cells that target the follicle stimulating hormone
receptor (FSHR). FSHR is found at immunologically relevant
levels exclusively on the granulosa cells of the ovaries.
Since the target is a hormone receptor, and the target-binding
domain is derived from its natural ligand, this technology is also
known as CER-T (Chimeric Endocrine Receptor T-cell) therapy, a new
type of CAR-T. Dr. Conejo-Garcia will also discuss the
ongoing Phase 1 clinical trial of this technology.
"I am excited to be presenting our novel FSHR-mediated CAR-T
technology to the researchers at Duke's Immuno-Oncology Research
Program and to share work we've been doing in developing CAR-T
treatments against solid tumors," stated Dr. Conejo-Garcia.
"I am pleased by the strong interest from the scientific community
in our unique CAR-T approach to treating ovarian cancer."
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company with a number of
programs addressing cancer and infectious disease. Anixa's
portfolio of therapeutics includes a cancer immunotherapy program
being developed in collaboration with Moffitt Cancer Center, which
uses a novel type of CAR-T, known as chimeric endocrine receptor
T-cell (CER-T) technology, and, with partner MolGenie GmbH, a
COVID-19 program focused on compounds targeting the Mpro
enzyme of SARS-CoV-2, which is largely conserved across all
recently identified variants. The company's vaccine portfolio
includes a novel vaccine being developed in collaboration with
Cleveland Clinic to prevent breast cancer – specifically triple
negative breast cancer (TNBC), the most lethal form of the disease
– as well as a vaccine to prevent ovarian cancer. These
vaccine technologies focus on immunizing against "retired" proteins
that have been found to be expressed in certain forms of
cancer. Anixa's unique business model of partnering with
world-renowned research institutions on clinical development allows
the company to continually examine emerging technologies in
complementary fields for further development and
commercialization. To learn more, visit www.anixa.com or
follow Anixa on Twitter, LinkedIn and Facebook.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form
8-K. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law. You are cautioned not to unduly rely on such
forward-looking statements when evaluating the information
presented in this press release.
Contact:
Mike
Catelani
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dr-jose-conejo-garcia-invited-to-present-keynote-address-at-duke-cancer-institute-will-discuss-anixa-biosciences-ovarian-cancer-car-t-therapy-301662872.html
SOURCE Anixa Biosciences, Inc.